Page last updated: 2024-11-04

rolipram and Koch's Disease

rolipram has been researched along with Koch's Disease in 1 studies

Research Excerpts

ExcerptRelevanceReference
"We analyzed the time to death in Mycobacterium tuberculosis-infected mice receiving type 4 PDE-Is (rolipram and cilomilast) and the impact on bacterial burden, time to clearance, and relapse when types 3 and 5 PDE-Is (cilostazol and sildenafil, respectively) and rolipram were added to the standard treatment."3.79Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. ( Ammerman, NC; Bishai, WR; Maiga, M; Maiga, MC; Murphy, R; Polis, M; Siddiqui, S; Tounkara, A, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Maiga, M1
Ammerman, NC1
Maiga, MC1
Tounkara, A1
Siddiqui, S1
Polis, M1
Murphy, R1
Bishai, WR1

Other Studies

1 other study available for rolipram and Koch's Disease

ArticleYear
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.
    The Journal of infectious diseases, 2013, Aug-01, Volume: 208, Issue:3

    Topics: Animals; Antitubercular Agents; Bacterial Load; Cilostazol; Disease Models, Animal; Drug Interaction

2013